Skip to main content
. Author manuscript; available in PMC: 2017 Jul 27.
Published in final edited form as: Hematol Oncol. 2016 Jan 25;35(2):215–224. doi: 10.1002/hon.2278

Table 1.

Descriptive characteristics of CLL cases.

Characteristics All CLL cases
(1986–2006)
N=79 (%)
Reduced set of
CLL casesa
N=65 (%)
P-
Valued
Bone marrow dose, median, mGy (range) 22.6 (0–1,536.2) 23.5 (0–1,536.2) 0.51
Age at first exposure, years, median (range) 45 (22–63) 46 (29–63) 0.50
  22–34 11 (13.9) 8 (12.3)
  35–39 15 (19.0) 12 (18.5)
  40–44 14 (17.7) 9 (13.9)
  45–49 17 (21.5) 16 (24.6)
  50–54 11 (13.9) 10 (15.4)
  55–63 11 (13.9) 10 (15.4)
Age at diagnosis, years, median (range) 57 (42–78) 57 (43–76) 0.94
  42–44 6 (7.6) 5 (7.7)
  45–54 25 (31.7) 20 (30.8)
  55–64 35 (44.3) 28 (43.1)
  65–74 9 (11.4) 9 (13.9)
  75–78 4 (5.1) 3 (4.6)
Latent period, years, median (range) 14 (1–20) 12 (1–20) 0.29
  0–4 7 (8.9) 7 (10.8)
  5–9 18 (22.8) 17 (26.2)
  10–14 22 (27.9) 20 (30.8)
  15–20 32 (40.5) 21 (32.3)
Urban / rural statusb 0.72
  Urban 62 (81.6) 52 (83.9)
  Rural 11 (14.5) 8 (12.9)
  Mixed 3 (4.0) 2 (3.2)
Smokingc 0.80
  Never/ former 36 (48.0) 28 (45.9)
  10–20 cigarettes per day 24 (32.0) 20 (32.8)
  More than 20 cigarettes per day 15 (20.0) 13 (21.3)
Alcohol consumptionb 0.99
  Never 20 (26.3) 16 (25.8)
  1–3 times per month 41 (54.0) 34 (54.8)
  Once per week – every day 15 (19.7) 12 (19.4)

Abbreviations: mGy, milligray.

a

Based on 65 cases with <2 years from start of chemotherapy to interview.

b

Among 76 subjects with known information on alcohol consumption and urban/rural status.

c

Among 75 subjects with known information on on smoking.

d

P-value for heterogeneity from the Wilcoxon Rank Sums test or one-way analysis of variance (ANOVA) for continuous variables and Kruskal Wallis tests for multi-level variables.